IPO Timeline Raw facts
Company Overview
| Stock Name | Bao Pharma-B |
|---|---|
| Stock Code | 02659 |
| Company Full Name | Shanghai Bao Pharmaceuticals Co., Ltd. |
| Industry | Biotech & Pharma |
| Principal Activities | We are a biotechnology company with one approved product and a diversified clinical pipeline, utilizing synthetic biotechnology to develop and provide recombinant biopharmaceuticals in China, with a focus on addressing target diseases with limited treatment options and complex drug manufacturing processes. |
| Listing Date | 2025-12-10 |
| Listing Rules Era | New Rules (after Aug 2025) |
| Listing Rules Chapter | Chapter 18A |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | Shanghai PRC |
| Business Address (Hong Kong) | Room 1919, 19/F, Lee Garden One 33 Hysan Avenue Causeway Bay Hong Kong |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | baopharma.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | Computershare Hong Kong Investor |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism B |
|---|---|
| Offer Price | HK$ 26.38 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 100 shares |
| Entry Threshold | HK$ 2,638 |
| Par Value | RMB 0.2 / shares |
| Offer Period | 2025-12-02 to 2025-12-05 |
| Global Offering Shares | 37,911,700 shares |
| HK Public Offer Shares (Initial) | 3,791,200 shares (10.0%) |
| Public Offer Lots (Initial) | 37,912lots (Pool A18,956lots,Pool B18,956lots) |
| International Placing Shares (Initial) | 34,120,500 shares (90.0%) |
| Offer Ratio | ~11.63% |
| Total Shares Post-IPO | 325,981,465 shares |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 20.1% |
| Clawback Tiers | Mechanism B: no clawback |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 1,000,110,646 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 100 | HK$ 2,638 |
| 2 lots | 200 | HK$ 5,276 |
| 3 lots | 300 | HK$ 7,914 |
| 4 lots | 400 | HK$ 10,552 |
| 5 lots | 500 | HK$ 13,190 |
| 6 lots | 600 | HK$ 15,828 |
| 7 lots | 700 | HK$ 18,466 |
| 8 lots | 800 | HK$ 21,104 |
| 9 lots | 900 | HK$ 23,742 |
| 10 lots | 1,000 | HK$ 26,380 |
| 15 lots | 1,500 | HK$ 39,570 |
| 20 lots | 2,000 | HK$ 52,760 |
| 25 lots | 2,500 | HK$ 65,950 |
| 30 lots | 3,000 | HK$ 79,140 |
| 35 lots | 3,500 | HK$ 92,330 |
| 40 lots | 4,000 | HK$ 105,520 |
| 45 lots | 4,500 | HK$ 118,710 |
| 50 lots | 5,000 | HK$ 131,900 |
| 60 lots | 6,000 | HK$ 158,280 |
| 70 lots | 7,000 | HK$ 184,660 |
| 80 lots | 8,000 | HK$ 211,040 |
| 90 lots | 9,000 | HK$ 237,420 |
| 100 lots | 10,000 | HK$ 263,800 |
| 200 lots | 20,000 | HK$ 527,600 |
| 300 lots | 30,000 | HK$ 791,400 |
| 400 lots | 40,000 | HK$ 1,055,200 |
| 500 lots | 50,000 | HK$ 1,319,000 |
| 600 lots | 60,000 | HK$ 1,582,800 |
| 700 lots | 70,000 | HK$ 1,846,600 |
| 800 lots | 80,000 | HK$ 2,110,400 |
| 900 lots | 90,000 | HK$ 2,374,200 |
| 1,000 lots | 100,000 | HK$ 2,638,000 |
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 2,000 lots | 200,000 | HK$ 5,276,000 |
| 3,000 lots | 300,000 | HK$ 7,914,000 |
| 4,000 lots | 400,000 | HK$ 10,552,000 |
| 5,000 lots | 500,000 | HK$ 13,190,000 |
| 6,000 lots | 600,000 | HK$ 15,828,000 |
| 7,000 lots | 700,000 | HK$ 18,466,000 |
| 8,000 lots | 800,000 | HK$ 21,104,000 |
| 9,000 lots | 900,000 | HK$ 23,742,000 |
| 10,000 lots | 1,000,000 | HK$ 26,380,000 |
| 12,500 lots | 1,250,000 | HK$ 32,975,000 |
| 15,000 lots | 1,500,000 | HK$ 39,570,000 |
| 18,956 lots | 1,895,600 | HK$ 50,005,928 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 6.77B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 8,599,391,046 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 4,071,152,855 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not applicable (loss-making) |
| Profit/Loss Status | Net loss RMB 364.4 million (2024) |
| Period-End Cash Balance | RMB 524.16 million |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | approximately RMB 1,530.6 million |
| First Day Close | HK$ 63.0 |
|---|---|
| First Day Open | HK$ 60.5 |
| First Day Change | 138.82% |
| First Day Volume | 7930300.0 |
| First Day Turnover | 448750000.0 |
| Use of Proceeds | 1、約53.5%(或493.2百萬港元)將用于核心產品(包括KJ017、KJ103及SJ02)的研發及商業化;
2、約17.7%(或162.8百萬港元)將用于推進其他現有管線產品及籌備相關登記備案;
3、約8.4%(或77.4百萬港元)將用于持續優化專有合成生物學技術平臺,以及研究和開發新候選藥物;
4、約10.4%(或95.9百萬港元)將用于提升及擴大生產能力;
5、約10.0%(或92.2百萬港元)將用作營運資金及一般公司用途。 |
Underwriting Syndicate
Service Providers
| Role | Institution |
|---|---|
| Legal Advisor to Company |
科律香港律师事务所 北京德恒律师事务所 |
| Legal Advisor to Sponsors/Underwriters |
凯易律师事务所 北京市通商律师事务所 |
| Auditor and Reporting Accountant | 安永会计师事务所 |
| Industry Advisor | 弗若斯特沙利文(北京)咨询有限公司上海分公司 |
| Receiving Banks | 中信银行(国际)有限公司 |
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 安科生物(香港)有限公司 | 112 HKD | 4,245,600 | 11.20% | 1.30% | 6 months | 2026-06-10 |
| 2 | Derivatives China Alpha Fund SPC(为及代表Derivatives China Fundamental Fund SP行事) | 50 HKD | 1,895,300 | 5.00% | 0.58% | 6 months | 2026-06-10 |
| 3 | 国泰君安证券投资(香港)有限公司(有关中和场外掉期) | 39 HKD | 1,463,200 | 3.86% | 0.45% | 6 months | 2026-06-10 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 劉彥君 | — |
| Company Secretary | Ms. Li Cui | Ms. Li Cui |
| Executive Director | 刘彦君 | Liu Yanjun |
| Non-Executive Director | 林佳陵 | Lin |
| Independent Non-Executive Director | 蔡仲曦 | Cai Zhongxi |
| Executive Director | 王征 | Wang Zheng |
| Non-Executive Director | 刁隽桓 | Diao Juanhuan |
| Independent Non-Executive Director | 曾凡一 | Zeng Fanyi |
| Executive Director | 谭靖伟 | Tan Jingwei |
| Non-Executive Director | Li Chen | |
| Independent Non-Executive Director | 鞠佃文 | Ju Dianwen |
| Executive Director | 李翠 | Li Cui |
| Independent Non-Executive Director | 张森泉 | Zhang Senquan |
| Independent Non-Executive Director | 楼俊文 | Lou Junwen |
| Independent Non-Executive Director | 成裕 | Cheng Yu |
| Independent Non-Executive Director | 蔡清清 | Cai Qingqing |
Major Shareholders
| Major Shareholders & Holdings | Dr. Liu beneficially owns 54,977,530 unlisted shares (32.03%) and 6,108,615 H shares (5.25%), and, through controlled corporations and acting-in-concert agreements, holds a larger proportion in aggregate. Ms. Wang beneficially owns 20,250,000 unlisted shares (11.80%) and 2,250,000 H shares (1.93%), and, through acting-in-concert agreements, holds a larger proportion in aggregate. Mr. Tan beneficially owns 7,500,000 unlisted shares (4.37%) and 7,500,000 H shares (6.44%), and, through acting-in-concert agreements, holds a larger proportion in aggregate. |
|---|
Market Sentiment
The retail tranche saw an overwhelming 3,526.34x oversubscription, signaling extreme investor enthusiasm for this 18A biotech listing. With a hit rate of just 13.41% and reallocation triggered, the overall subscription was heavily congested, reflecting strong demand despite the high risk profile of pre-revenue biotech firms. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
A notable tier anomaly: A-tail applicants needed 100,000 lots for an expected allocation of just 1 lot, while B-head applicants required double that (200,000 lots) for the same 1-lot expected return. This creates high capital inefficiency at both tiers, with B-head incurring significantly higher margin interest costs for identical share allocation. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice. Broker fee structures vary; actual costs may differ.)
Demographics
Demographic data for this IPO is not available in the source filings — mainland participation rate, gender split, and regional concentration are all reported as zero or null. Without such breakdown, it’s impossible to comment on the investor profile, though high oversubscription often correlates with strong mainland interest in HK biotech offerings. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice. Data may contain errors or omissions from source documents — verify against official HKEX filings.)




